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and the cervical collar. A dose volume histogram was 
generated and a dosimetric correlation of MRD with dose to 
2cc (D2cc), dose to 1cc (D1cc), maximum and mean rectal 
dose was calculated using spss software version 19. 
Results: The mean MRD was 3.11cm (range 2.32-3.77cm). 
D1cc, D2cc, mean rectal dose and maximum rectal doses 
were 3.51 Gy, 3.04 Gy, 1.63 Gy and 4.95 Gy per treatment, 
respectively. Statistical analysis revealed an increase in D2cc 
(p=0.02) and D1cc (p=0.05) with increasing rectal distension. 
Further it is possible to predict the increase in D2cc with 
increasing rectal distension using the linear regression model: 
'Increase in D2cc in cGy = 17.74 + 92.22 x Increase in rectal 
distension in cm'. 
 
Conclusions: D2cc increases significantly with increasing 
rectal distension in HDR brachytherapy for cervical cancer 
patients. Minimizing rectal distension by simple measures like 
overnight fasting, mild laxatives and enema are likely to 
minimize potential rectal toxicity. Hence efforts to decrease 
rectal distention during brachytherapy should be considered.  
 
PO-0751   
Early stage endometrial cancer treated with surgery and 
no adjuvant treatment ñ to follow-up or not? 
M.J. Kyle1, A. Stillie1, S. Symeonides1 
1Edinburgh Cancer Centre, Western General Hospital, 
Edinburgh, United Kingdom  
 
Purpose/Objective: Endometrial cancer is the commonest 
gynaecological malignancy with an increasing incidence. It is 
unclear whether patients with early stage endometrial cancer 
treated with surgery and no adjuvant therapy require regular 
gynaecological follow-up. 
Materials and Methods: Retrospective analysis of all cases of 
early stage endometrial cancer treated with surgery and no 
adjuvant therapy presenting with recurrence over a thirteen 
year time period in a single centre. Case notes and electronic 
records were reviewed to determine whether the recurrence 
presented symptomatically or was detected clinically on 
follow-up. The intent of treatment at recurrence was 
analysed to determine the 2-year survival for this patient 
group. 
Results: 35 patients were included, who presented with 
recurrence between 2000 and 2013. 10 patients (29%) were 
detected clinically on routine follow-up with 25 patients 
(71%) presenting symptomatically. 20 patients (57%) were 
treated with palliative intent (7 chemotherapy, 8 External 
Beam Radiotherapy (EBRT), 4 hormone treatments and 1 best 
supportive care) and 15 patients (43%) were treated with 
radical intent (9 EBRT followed by brachytherapy, 4 
brachytherapy alone and 2 receiving EBRT alone). Median 
follow-up was 22 months. Median survival overall was 23 
months, with palliative treatment was 10 months and with 
radical treatment was 53 months. 2-year survival following 
recurrence overall was 51.6%, following radical treatment 
was 78.5%, and following palliative treatment was 29.4%.  
Conclusions: With 71% of patients presenting with recurrence 
having symptoms, it would appear on the surface to be 
reasonable to alter the model of follow-up to be more 
patient-centred, with symptoms triggering referral rather 
than routine review. However, in view of 80% of patients 
whose recurrence is detected at Routine Follow-Up, going on 
to have radical treatment, it may be more appropriate to 
offer patients the choice of Routine Follow-Up or a telephone 
review/self-referral service. In times of pressure on NHS 
resources this may be a suitable way of managing this cohort 
of patients. 
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Purpose/Objective: The position of the vagina could be 
highly variable due to differences of bladder and rectal 
filling. In order to ensure adequate target coverage, RTOG 
first introduced ITV accounting for individualized organ 
motion affected by bladder filling. We investigate the 
magnitude of vaginal displacement along the treatment in 
patients treated with post-operative IMRT for gynaecological 
cancer. We evaluate the subsequent dosimetric coverage loss 
and look for any correlation with bladder and rectal filling. 
Materials and Methods: We retrospectively analyzed 27 
consecutive patients treated in our institution between July 
2012 and July 2014 with IMRT for post-operative treatment of 
gynaecological cancer.  
All patients underwent empty and full bladder CT simulation 
(CT planning). This procedure was repeated as a control 3 
weeks after (CT-control). Both sets of CTs were registered. 
The delineation of the volumes and the definition of ITV were 
performed following the RTOG guidelines in both CTs. 
ITV displacement was measured as the coordinates difference 
(in three axes) between the center-of-mass of both ITV, 
expressed in absolute value. With these values we calculated 
the 3D vector. 
The PTV was created by adding 0.7cm (margin) to ITV and 
CTV-node. Treatment planning was done on full bladder CT-
planning with IMRT. Plans were optimized and normalized to 
deliver 100% prescribed dose to 97% of PTV. 
These plans were recalculated (but not optimized) on the full 
bladder CT-control. 
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ITV coverage was then evaluated by comparing the volume 
covered by the prescription isodose on full bladder CT-
planning and CT-control. 
Patients were asked to have full bladder but they did not 
follow specific recommendation for rectum. 
We investigated the correlation of 3D vector and loss of 
dosimetric coverage with bladder volume, rectal volume, 
maximum rectal diameter and AP rectal diameter at tip of 
coccyx level. 
Results: The ITV displacements turned out to be (mean ± SD) 
0.17 ± 0.12cm (range 0.01-0.50) in Left-Right, 0.41 ± 0.31cm 
(0.03-1.26) in anteroposterior and 0.35 ± 0.28cm (0.00-0.93) 
in craniocaudal direction. Mean 3D vector was 0.64 ± 0.32cm 
(0.09-1.30). 
All patients with 3D vector<0.7 cm (59.3%) showed a loss of 
coverage less than 10%. The rest of patients had a 3D 
vector>0.7 cm, but only 15% (4/27) had a loss of coverage 
higher than 10% (range 16.4-20.2%). 
We found a correlation between the 3D vector and the loss of 
coverage (Pearson correlation 0,51; p=0,007). 
We did not find any significant correlation of different rectal 
and bladder parameters with the 3D vector and loss of 
dosimetric coverage.  
Conclusions: Although vaginal movement was observed for 
the patients, only few of them showed a significant loss of 
coverage. We were unable to find that rectum and bladder 
filling had significant effect on the ITV displacement or loss 
of dosimetric coverage. Vaginal ITV is a good procedure to 
ensure an acceptable dosimetric coverage. 
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Purpose/Objective: Aim of this study was to assess the role 
of whole-body 18F-fluorodeoxyglucose Positron Emission 
Tomography (18F-FDG PET) and Magnetic Resonance Imaging 
(MRI) in the management of cervical cancer. 
Materials and Methods: In pretreatment staging, 93 patients 
with histological diagnosis of cervical cancer, underwent 18F-
FDG PET in addition to routine protocol including 
International Federation of Obstetrics and Gynecology (FIGO) 
staging and MRI.  
Results: In all patients both 18F-FDG PET and MRI detected 
the primary tumor. 
In 67 patients (72%) the result of 18F-FDG PET and MRI was the 
same, but in 29 patients (31.2%) the result was different: 18F-
FDG PET detected pelvic nodal metastases not seen by MRI in 
11 cases (11.8%) and MRI detected pelvic nodal metastases 
not seen by 18F-FDG PET in 15 cases (16.1%). In 3 cases (3.2%) 
both exams was positive, but 18F-FDG PET showed a higher 
number of pelvic nodal metastases than MRI. Furthermore in 
20 cases (21.5%) 18F-FDG PET showed para-aortic nodal 
metastases. 
Conclusions: Integrating two imaging techniques allowed the 
identification of a higher number of pelvic nodal metastases, 
achieving a better initial staging and subsequent appropriate 
treatment. Finally, whole-body 18F-FDG PET was useful for 
staging extrapelvic nodal metastases.  
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Purpose/Objective: Application of conformal radiotherapy 
(CRT) with different regimes of dose fractionation in patients 
with locally advanced cervical cancer is a promising 
technique to increase the treatment effectiveness. The 
purpose of the presented work was to evaluate the efficacy 
and toxicity of the regime of accelerated fractionation during 
CRT and in vivo cytogenetic monitoring in patients with 
locally advanced cervical cancer. 
Materials and Methods: A course of combined radiotherapy 
for 37 patients with locally advanced cervical cancer treated 
on the phase I with CRT by Clinac 2100/CD linear accelerator 
with 6 MeV bremsstrahlung radiation in two regimes: 
fractionated regime of 1,3 Gy per fraction delivered twice 
daily with 4 h interval to the total focal dose of 39 Gy for the 
tumor node and 44 Gy for the pelvic lymph nodes ( group I, 
n=16) vs. standard fractionation regime of single 2,0 Gy dose 
exposure to the total focal dose of 45-46 Gy on the pelvic 
area (group II, control, n=21). In phase II of the radiotherapy 
course intracavitary brachytherapy with high-activity ??60 
source («Gyne Source») was used in the treatment of all 
patients in the regime of single 5 Gy dose exposure of the p. 
A 2 given twice daily to the total dose of 35-40 Gy/ 7-8 
fractions. Peripheral blood lymphocytes (PBL) of the cancer 
patients were the objects of cytogenetic analysis 
(chromosomal aberrations). Blood sampling in patients of 
group I was performed three times: before the CRT, and 
during the first treatment exposure; in patients of group II - 
twice: before the CRT and 24 h after first fraction.  
Results: In group I complete regression (CR) of tumors was 
registered in 21,4%, partial tumor regression (PR) - in 50,0%, 
stabilization process - in 28,6% of patients; in group II 
(control) it was 18,3%, 42,1% and 39,6% of patients with 
locally advanced cervical cancer, respectively. 
Analysis of the in vivo release of radiation markers in PBL of 
CC patients showed that accumulation rate of dicentric and 
ring chromosomes after the first treatment at the regime of 
dose accelerated fractionation (group I) was significantly 
lower in comparison with standard fractionation schedule 
(group II): 1,01 ± 0,05 per 100 metaphases after the first 
fraction of 1,3 Gy, 1,9 ± 0,15 per 100 metaphases after total 
daily dose of 2,6 Gy and 2,6 ± 0,1 per 100 metaphases 
analyzed, respectively.  
Conclusions: Analysis of the direct efficacy and toxicity of 
the treatment of the patients with locally advanced cervical 
